Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics

• DOI: 10.1111/resp.14506
• Publication Date: 2023-04-28T12:59:17Z
• Authors: Bilal Malik; Nathan W. Bartlett; John W. Upham; Kristy S. Nichol; John Harrington; Peter A. B. Wark
• Keywords: Thymic stromal lymphopoietin; Innate lymphoid cell; Omalizumab

Abstract Background and Objective Type 2 (T2) innate lymphoid cells (ILC2s) contribute to airway inflammation disease in asthma. We hypothesize that ILC2s isolated from people with severe allergic eosinophilic asthma would exhibit an enhanced T2 inflammatory activity be altered following treatment mepolizumab omalizumab. compare peripheral blood (PB) ILC2's proliferative capacity, IL‐5 IL‐13 secretion phenotype between healthy without (HC), non‐asthma (NAA), mild (MA) (SA) subjects. then determined the impact of 6 months either or omalizumab on physiology SA Methods were sorted cultured presence IL‐2, IL‐25, IL‐33 thymic stromal lymphopoietin (TSLP) for 14 days. proliferation, phenotypes functions assessed using flowcytometry. The response was reassessed clinically successful subjects Results demonstrated increased TSLP receptor (TSLPR), GATA3 NFATc1 protein expressions release. also capable releasing IL‐6 stimulation. Mepolizumab reduced capacity expression TSLPR, NFATc1. Both associated release IL‐13, only IL‐6. Conclusion active typified by IL‐5, markers activation.